brentuximab vedotin
seagen,takeda
['lymphoma', 'echelon-1', 'brentuximab vedotin', 'improve ', 'hodgkin']
first-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage iii/iv classical hodgkin lymphoma: updated analysis of echelon-1. 
Karl Schwartz,  formerly: patient representative to FDA, president of PAL, CIRB member, NCI Steering Cmt, Vail Methods Workshop faculty. https://t.co/BOJsbY7TCg